Endocrine Abstracts

Objective: Quality of life is currently considered a major factor in the assessment of disease outcome. The aim was to assess quality of life in acromegaly and the effect of somatostatin analogues on it.Design: This study included 101 patients with acromegaly, mean age 59.51±1.35 years (mean ± S.E.M.), with a disease duration of 12.88±0.96 years. All subjects completed the Acromegaly Quality of Life Questionnaire (AcroQoL) w...

Introduction: Several studies have suggested that patients with acromegaly have an increased risk of thyroid, colorectal, breast and prostate tumors. We determined the prevalence of malignant neoplasms in patients with acromegaly in a single Greek Centre during the years 1995–2015.Methods: We evaluated cancer risk in a cohort of 110 patients (M/F 48/62, age 58.63±13.8 years, range 30–86) with acromegaly. Mean age at diagnosis of acromegaly...